Savara Pharmaceuticals, which creates drugs focused on rare respiratory diseases, announced it has acquired the assets of Serendex Pharmaceuticals.
The addition of Serendex adds new drugs to its portofolio including Serendex’s flagship product, Molgradex, an inhaled drug in later stage clinical trials in Europe and Japan to treat autoimmune pulmonary alveolar proteinosis.
The acquisition is subject to Savara’s shareholder approval and regulatory approval.
Serendex, founded in 2008 in Copenhagen, Denmark, makes inhalation therapies to treat patients for rare respiratory conditions. The compay went public on the Olso Stock Exchange in 2014 and was delisted in May.
“The acquisition is a transformational milestone for Savara, expanding our pipeline of orphan respiratory drugs with an exciting product for a highly debilitating disease with no approved medicinal treatments,” Rob Neville, Chief Executive Officer of Savara Pharmaceuticals, said in a news release.
Austin-based Savara Pharmaceuticals makes drugs to treat serious and life-threatening rare respiratory diseases. Its lead product is AeroVanc, an antibiotic being developed for the treatment of persistent MRSA infection in people with Cystic Fibrosis. The drug’s Phase III clinical trials are expected to begin later this year.